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Although there are a number of well-characterized genetic defects that lead to increased risk of thrombosis, little
information is available on the relative importance of genetic factors in thrombosis risk in the general population.
We performed a family-based study of the genetics of thrombosis in the Spanish population to assess the heritability
of thrombosis and to identify the joint actions of genes on thrombosis risk and related quantitative hemostasis
phenotypes. We examined 398 individuals in 21 extended pedigrees. Twelve pedigrees were ascertained through a
proband with idiopathic thrombosis, and the remaining pedigrees were randomly ascertained. The heritability of
thrombosis liability and the genetic correlations between thrombosis and each of the quantitative risk factors were
estimated by means of a novel variance component method that used a multivariate threshold model. More than
60% of the variation in susceptibility to common thrombosis is attributable to genetic factors. Several quantitative
risk factors exhibited significant genetic correlations with thrombosis, indicating that some of the genes that influence
quantitative variation in these physiological correlates also influence the risk of thrombosis. Traits that exhibited
significant genetic correlations with thrombosis included levels of several coagulation factors (factors VII, VIII, IX,
XI, XII, and von Willebrand), tissue plasminogen activator, homocysteine, and the activated protein C ratio. This
is the first study that quantifies the genetic component of susceptibility to common thrombosis. The high heritability
of thrombosis risk and the significant genetic correlations between thrombosis and related risk factors suggest that
the exploitation of correlated quantitative phenotypes will aid the search for susceptibility genes.
Introduction
Thrombosis is a common cause of morbidity and mor-
tality in industrialized nations. Both venous and arterial
forms of thrombosis are of great public-health impor-
tance. Although there is little direct information on prev-
alence, retrospective and prospective data (Coon et al.
1973; Anderson et al. 1991; Nordstrom et al. 1992)
suggest a minimum lifetime prevalence of 5%–10% for
deep-vein thrombosis. After the inclusion of arterial
thromboses, other venous thromboses, and undiagnosed
thrombotic conditions, the true lifetime prevalence of
thrombosis must be substantially 110%.
The canonical causes of thrombosis include both en-
vironmental and genetic factors (Rosendaal 1999). The
high prevalence of thrombosis and its known environ-
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mental influences, such as smoking and oral contracep-
tive use, suggest that multiple genes of varying effects
will be involved in determining susceptibility to throm-
bosis. Such complex oligogenic inheritance is also likely
to involve gene-gene and gene-environment interactions
(Hasstedt et al. 1998). Although there are a number of
well-characterized genetic defects that lead to increased
thrombotic risk (Lane et al. 1996), it is unlikely that
these comparatively infrequent mutations constitute the
primary genetic influences on risk of common late-onset
thrombosis. In fact, very little information is available
on the relative importance of genetic factors in throm-
bosis risk in the general population. Because of the pau-
city of family-based studies, there are no extant esti-
mates of the heritability of thrombosis risk.
The physiological cascade that underlies the normal
formation of thrombin and the pathological endpoint
of thrombosis is complex, with many components in-
volved in the coagulation and fibrinolytic pathways.
The identification of quantitative risk factors for throm-
bosis has accelerated in recent years. Numerous he-
mostatic factors—including fibrinogen, factor VII, fac-
tor VIII, von Willebrand factor, and homocysteine—
have been implicated as possible concomitants of both
Souto et al.: Genetics of Thrombosis: The GAIT Study 1453
venous (Koster et al. 1994, 1995; MacCallum et al.
1995; den Heijer et al. 1996) and arterial thrombosis
(Meade et al. 1986; Hamsten et al. 1987; Ernst and
Resch 1993; Ridker et al. 1993; Folsom et al. 1997;
Nygard et al. 1997). Regardless of their causal rela-
tionships with thrombosis, such correlated phenotypes
can provide additional information about the genetic
basis of thrombosis risk. Recent advances in statistical
genetics allow the simultaneous examination of the ge-
netic and environmental sources of correlations between
such continuous physiological measures and discrete
disease outcomes (Williams et al. 1999b) through the
examination of data from large families. Such ap-
proaches, when coupled with modern molecular genetic
technologies, will soon permit the localization and iden-
tification of the quantitative trait loci (QTLs) that un-
derlie thrombosis risk. Prior to embarking on the po-
tentially expensive search for the actual loci involved,
it is prudent to evaluate the magnitude of genetic effects
on thrombosis and to test for the pleiotropic effects of
genes on both risk factors and disease.
As a first step toward the ultimate goal of the iden-
tification of novel genes involved in thrombosis suscep-
tibility, we performed a family-based study of the ge-
netics of thrombosis in the Spanish population. This
study design has allowed us to quantify the heritability
of thrombosis and to identify the joint actions of genes
on thrombosis risk and a number of related quantitative
phenotypes. Previous analyses of these 27 quantitative
phenotypes have already demonstrated strong herita-
bilities for most of these traits (Souto et al. 2000). The
majority of the heritabilities ranged between 0.22 and
0.55, with somewhat higher values seen for factor XII
(0.67), activated protein C resistance ratio (0.71), and
activated partial thromboplastin time (0.83), and some-
what lower values observed for D-dimer (0.11) and tis-
sue factor (0.17).
Subjects and Methods
Study Population and Diagnosis
The Genetic Analysis of Idiopathic Thrombophilia
(GAIT) Study is composed of 21 extended families, 12
of which were ascertained through a proband with
thrombophilia and 9 of which were obtained randomly.
Thrombophilia was defined as multiple thrombotic
events (at least one of which was spontaneous), a single
spontaneous episode of thrombosis with a first-degree
relative also affected, or onset of thrombosis at age !45
years. Ten of the 12 thrombophilic probands had onset
at age !45 years, 8 had multiple episodes of thrombosis,
and 2 probands were ascertained on the basis of family
history. Diagnoses of the thrombophilic probands were
verified by objective methods. Thrombosis in these in-
dividuals was considered idiopathic because of exclusion
of all biological causes of thrombosis, including anti-
thrombin deficiency, Protein S and C deficiencies, acti-
vated protein C resistance, plasminogen deficiency, hep-
arin cofactor II deficiency, Factor V Leiden, dysfibro-
genemia, lupus anticoagulant, and antiphospholipid an-
tibodies, known at the time of recruitment (1995–97).
A total of 398 individuals (with a mean of 19 indi-
viduals per family) were examined. Most pedigrees con-
tained three generations, although eight families had
four generations and one family had five. Subjects had
a mean age at examination of 37.7 years, and there were
approximately equal numbers of males and females. The
composition of the families and the collection of lifestyle,
medical, and family-history data have been described
elsewhere (Souto et al. 2000). Reported history of
thrombosis in family members was verified by exami-
nation of medical records, when available. Although
some deceased family members had a history of throm-
bosis, only individuals interviewed and examined in per-
son were included in the analyses. The primary residence
of each subject was also determined, to assess the con-
tribution of shared environmental influences (such as
diet) common to members of a household. The study
was performed according to the Declaration of Helsinki
of 1975, and all adult patients provided informed con-
sent for themselves and for their minor children.
Laboratory Measurements and Techniques
A total of 27 quantitative phenotypes were measured
in the plasma of each individual. None of the partici-
pants was being treated with anticoagulant therapy at
the time of blood drawing. Activated partial thrombo-
plastin time (APTT), prothrombin time (PT), coagula-
tion factors (FII, FV, FVII, FVIII, FIX, FX, FXI, and
FXII), functional protein S, and the activated protein C-
sensitivity ratio (APCR) were measured by automated
coagulometry. Antithrombin, protein C, heparin cofac-
tor II, plasminogen, and plasminogen activator inhibitor
were measured by chromogenic methods. Fibrinogen
was measured by the Clauss method (Clauss 1957). To-
tal and free protein S, tissue plasminogen activator (t-
PA), D-dimer (DD), tissue factor (TF), and von Wille-
brand factor (vWF) were assayed by use of commercially
available ELISA kits. Histidine-rich glycoprotein (HRG)
was measured by electroimmunoassay, tissue factor
pathway inhibitor (TFPI) by a functional method (Sand-
set et al. 1991), and homocysteine by a fluorimetric
method (Hyland and Bottiglieri 1992). ABO blood
groups and Factor V Leiden genotypes were assessed by
means of standard techniques. Details of phenotype as-
says are available in Souto et al. (2000).
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Statistical Genetic Analysis
The heritability (the proportion of the total pheno-
typic variability attributable to genetic effects) of sus-
ceptibility to thrombosis was evaluated by means of a
pedigree-based maximum-likelihood method that mod-
els affection status as a threshold process (Duggirala et
al. 1997, 1999a; Williams et al. 1999b). Although dis-
ease status is usually operationalized as a discrete trait,
with individuals scored as unaffected or affected, it is
generally assumed that there is an unobservable contin-
uous trait, termed “liability” or “susceptibility,” that
determines affection status. If an individual’s liability
score exceeds some specified threshold, disease results;
if it is below the threshold, the individual is unaffected.
The threshold is placed in an age- and sex-specific man-
ner, to produce the appropriate population prevalence.
A specific individual’s liability is only known to be above
or below the threshold, depending on the individual’s
affection status, and an integral over the appropriate
region of the curve is used to estimate each person’s
liability value. Since such continuous processes deter-
mine most biological phenomena, it is useful to make
inferences on the underlying continuous scale, which is
more consistent with current models of gene action.
Threshold models permit such inferences regarding the
latent underlying quantitative scale to be made. To use
a threshold model, some weak assumptions regarding
the form of the underlying continuous process are nec-
essary. For genetic modeling, we assume that the un-
derlying liability distribution is normal, and we calculate
the joint probability of observing the disease statuses
of family members by using a multivariate normal dis-
tribution that allows for correlations among family
members.
The analysis of heritability of thrombosis suscepti-
bility was performed using the variance component
method. The total phenotypic variance in thrombosis
susceptibility was partitioned into three components: (1)
an additive genetic variance, caused by the sum of the
average effects of all the genes that influence thrombosis;
(2) a shared environmental variance, caused by the ef-
fects of environmental factors that are common to
households; and (3) a random environmental variance
specific to each individual. The random environmental
variance also absorbs nonadditive genetic effects, such
as interactions between alleles within loci (dominance
effects), interactions between alleles at different loci (ep-
istatic effects), and effects caused by gene-environment
interactions. Therefore, such models will generally un-
derestimate the role of genetics in the determination of
the trait.
With this approach, the relative components of var-
iance can be estimated by use of maximum-likelihood
estimation. Evaluation of the likelihood function for a
pedigree involves high dimensional integration of a mul-
tivariate normal distribution. The limits of integration
may be different for each individual, depending on af-
fection status as well as on any covariates that are in-
troduced as fixed effects in the model for the mean li-
ability. In the current analyses, these covariates included
age and sex.
To study the genetic relationships between thrombosis
susceptibility and quantitative variation in hemostatic
parameters, we used a new mixed discrete/continuous
trait variance component analysis (Williams et al.
1999b). This analysis used a modified variance com-
ponent method to accommodate a mixture of discrete
and continuous data and allows the phenotypic corre-
lations between these traits to be decomposed into fac-
tors caused by common genetic influences and common
environmental influences on the two traits. Examination
of the underlying determinants of phenotypic correla-
tions provides information on the role of pleiotropic
genetic effects.
All the extant epidemiological evidence for the rela-
tionship between thrombosis and hemostatic parameters
is based on the evaluation of phenotypic correlations.
However, the decomposition of phenotypic correlations
into genetic and environmental components is poten-
tially valuable, since hidden relationships between traits
can be revealed (Comuzzie et al. 1996). For example, if
trait and trait , where g and ey p g  e y p g  e1 1 1 2 2 2
denote genetic and environmental effects, the observed
correlations between the phenotypic traits are deter-
mined by the latent genetic and environmental corre-
lations between the component variables. By studying
both traits in extended families, we can estimate both
the genetic (rg) and the environmental (re) correlations
between traits. The phenotypic correlation (rp) is derived
from these two constituent correlations and the herita-
bilities of the traits:
2 2 2 2  ( ) ( ) ( )r p h h r  1 h 1 h rp 1 2 g 1 2 e .
We have incorporated the threshold model (Duggirala
et al. 1997, 1999a) and the mixed discrete/continuous
trait variance component method (Williams et al. 1999b)
into our statistical genetic computer package, SOLAR
(Almasy and Blangero 1998). All statistical genetic anal-
yses were performed using SOLAR, with these modifi-
cations. Estimates of variance component parameters,
including the heritabilities of thrombosis and the quan-
titative measures and all the phenotypic, genetic, and
environmental correlations between thrombosis and the
quantitative phenotypes, were obtained by use of max-
imum-likelihood estimation. All hypothesis tests were
performed using likelihood-ratio test statistics (Kendall
and Stuart 1972; Self and Liang 1987).
Because 12 of the 21 pedigrees were ascertained
Souto et al.: Genetics of Thrombosis: The GAIT Study 1455
Table 1
Number and Percent of Individuals in Each Diagnostic Category of









Deep-vein thrombosis 28 (52.8) 40.3
Pulmonary embolism 9 (17.0) 45.6
SFT 14 (26.4) 41.2
Other venous thrombosis 3 (5.7) 58.0
Any venous thrombosis 40 (75.5) 39.7
Arterial thrombosis:
Myocardial infarction 4 (7.5) 66.5
Angina pectoris 4 (7.5) 57.3
Ischemic stroke 6 (11.3) 61.0
Transient ischemic attack 5 (9.4) 55.4
Any arterial thrombosis 17 (32.1) 61.0
Any thrombosis 53 (100.0) 44.5
NOTE.—Some individuals are represented in multiple diagnostic
categories.
through a thrombophilic proband, all analyses included
an ascertainment correction, to allow unbiased estima-
tion of parameters relevant to the general population.
To achieve this, the likelihood for each family ascer-
tained through a thrombophilic proband was condi-
tioned on the phenotype of the proband (Hopper and
Mathews 1982; Boehnke and Lange 1984). Since two
families were ascertained, in part, because of the family
history of the proband, analyses were repeated condi-
tioning on both the original proband and the affected
first-degree relative in these two families. However, the
results of the analyses were unchanged.
Results
Characteristics of Affected Individuals
A total of 53 people with venous or arterial throm-
bosis were identified, 47 in the families ascertained
through thrombophilic probands and 6 in the randomly
ascertained families. The number of affected individuals
per family ascertained through a thrombophilic proband
was 2–8, with a mean of 3.9. The distribution of throm-
botic subjects in these extended families included many
instances of affected first-degree relatives (siblings or
parents and children) but also grandparents, aunts or
uncles, and first cousins. Eight of these families con-
tained cases of both arterial and venous thrombosis. Two
of the randomly ascertained families each had two in-
dividuals with thrombophlebitis. One of these was a
parent-child pair, but the other consisted of two unre-
lated individuals (in-laws). One randomly ascertained
family had a single individual with deep-vein throm-
bosis, and one had an individual with transient ischemic
attacks.
There were slightly more affected females ( ,np 31
58.5%) than males ( , 41.5%), and the age atnp 22
diagnosis of first thrombosis was 12–76 years, with a
mean of 44.5 (table 1). When venous and arterial throm-
bosis were considered separately, 40 individuals, with
an average age at first diagnosis of 39.7 years, had one
or more diagnoses of venous thrombosis; 17 individuals,
with an average age at first diagnosis of 61.0 years, had
one or more arterial thromboses. The early observed
age at diagnosis for venous thrombosis is partially a
function of the ascertainment criteria. Deep-vein throm-
bosis was the most common condition ( ) andnp 28
superficial thrombophlebitis (SFT) the second most com-
mon ( ). Fifteen (28%) of the 53 affected peoplenp 14
had multiple thrombotic diagnoses, and five (9.4%) of
these people had both venous and arterial events. Twelve
individuals had deep-vein thrombosis and one to three
other venous or arterial thromboses; one person had
ischemic stroke and transient ischemic attacks; one per-
son had SFT and pulmonary embolism; and one had
SFT and other venous thrombosis.
Genetic Determinants of Liability to Thrombosis
The evidence for a strong genetic influence on risk of
thrombosis was striking. Liability to thrombosis exhib-
ited an additive genetic heritability of 0.61
), indicating that, after correction50.16 (Pp 9 # 10
for the effects of age and sex, 61% of the variation in
liability to thrombosis at the population level can be
attributed to genetic factors. No shared environmental
effects were found among members of a household for
liability to thrombosis. Therefore, the above heritability
estimates are unlikely to be inflated by nongenetic cor-
relations among family members, and environmental
factors shared by members of a household, such as diet,
do not have major effects on thrombosis susceptibility.
When the diagnoses considered are restricted to venous
thrombosis, excluding arterial thrombotic events, the ad-
ditive genetic heritability is not significantly different
from that obtained with any thrombosis. Similarly, when
venous and arterial thrombosis are analyzed jointly as
two distinct traits, the phenotypic correlation between
these two manifestations of thrombosis is .333 (Pp
), and the genetic correlation is .55 ( ). Ad-.0126 Pp .09
ditionally, the genetic correlation is not significantly dif-
ferent from 1. Both the robustness of the heritability
when combining across venous and arterial diagnoses
and the fact that the genetic correlation is not signifi-
cantly different from one strongly suggest that arterial
and venous thromboses are highly genetically correlated
and that our broad phenotypic characterization will be
useful to increase the power to detect genetic effects.
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Table 2
Phenotypic, Genetic, and Environmental Correlations of
Quantitative Risk Factors with Thrombosis
Phenotypea rp P
b rg P re P
b
APCR .230 .0003 .650 1#106 .669 .0006
FVII .025 NS .354 .0564 .568 .0091
FVIII .288 .0002 .689 .0005 .126 NS
FIX .151 .0787 .597 .0131 .198 NS
FXI .209 .0180 .564 .0245 .070 NS
FXII .172 .0339 .351 .0500 .145 NS
Homocysteine .227 .0018 .652 .0015 .028 NS
t-PA .180 .0002 .752 .0070 .099 NS
vWF .261 .0010 .729 .0005 .181 NS
a Only phenotypes with one or more correlations having P ! .05
are shown.
b NS p nonsignificant ( ).P 1 .10
Correlations between Thrombosis Liability and
Quantitative Risk Factors
Table 2 shows the results of bivariate genetic analyses
of thrombosis, with each of the quantitative physiolog-
ical traits considered. Only the nine quantitative traits
showing at least one significant correlation ( ) areP ! .05
presented. Of these, seven exhibit significant phenotypic
correlations with thrombosis susceptibility, eight dem-
onstrate significant genetic correlations with thrombosis,
and only two exhibit significant environmental corre-
lations. The largest phenotypic correlations (FrpF 1 0.2)
are seen between FVIII, vWF, APCR, FXI, homocysteine,
and thrombosis.
The genetic correlations provide strong evidence for
significant pleiotropy underlying the covariation be-
tween several of the quantitative traits and thrombosis
risk. Those quantitative measures exhibiting the largest
genetic correlations (FrgF 1 0.6) with thrombosis include
vWF, t-PA, FVIII, homocysteine, and APCR. The only
traits to exhibit significant environmental correlations
with thrombosis were APCR and FVII. Table 2 provides
a good demonstration of how low-phenotypic correla-
tions may misrepresent the true underlying relationships.
Both FIX and FVII failed to show significant phenotypic
correlations with thrombosis. However, both provide
strong evidence for correlations between genetic effects
(FIX) and environmental effects (FVII) with thrombosis.
Similarly, the genetic and environmental correlations be-
tween APCR and thrombosis are of similar magnitudes
but exhibit different directions. When such differences
in sign appear, the phenotypic correlation is attenuated,
although the underlying components suggest much
stronger correlations. Relationships between APCR and
thrombosis were unchanged when the presence of the
Factor V Leiden mutation (there were nine heterozygotes
in the sample) was statistically controlled. Similarly, the
correlations between FVIII and thrombosis were un-
changed when ABO blood type was incorporated into
the model.
Discussion
This is the first study that formally documents the large
genetic component for risk of thrombosis. By gathering
and analyzing data on extended pedigrees that have been
methodically ascertained to allow general population in-
ferences, we have begun to fill a critical gap in the study
designs used in thrombosis genetics. Researchers in he-
mostasis/thrombosis generally have not actively pursued
family studies, except for the occasional serendipitous
collection of unusual families with high densities of af-
fected individuals. Therefore, most of our knowledge
regarding the genetic factors involved in common throm-
bosis has been limited to association studies that use
case-control designs to look at known polymorphic var-
iations in candidate genes (Poort et al. 1996; Rosendaal
1997; Rosendaal et al. 1997; Iacoviello et al. 1998).
Although such studies provide important indirect evi-
dence for the presence of genetic effects, they have a
number of weaknesses. These include their limitation to
known candidate genes, their propensity for type I errors
caused by hidden population stratification, the lack of
direct evaluation of familial transmission, and their gen-
eral inability to reliably estimate the relative importance
of genetic factors in determining within-population var-
iation in thrombosis risk. Family-based studies eliminate
these problems, although their costs tend to be greater.
The high additive genetic heritability that we esti-
mated suggests that whole-genome approaches to lo-
calizing and characterizing QTLs that underlie throm-
bosis susceptibility will be feasible. The magnitude of
the additive genetic heritability is greater than or equal
to that seen in other common complex diseases such as
type II diabetes (Duggirala et al. 1999a), gallbladder
disease (Duggirala et al. 1999b), alcoholism (Williams
et al. 1999a), and obesity (Comuzzie et al. 1997), whose
contributing QTLs are currently being pursued through
genome scans.
This is also the first study that attempts to decompose
the phenotypic correlations between quantitative phys-
iological risk factors and thrombosis into genetic and
environmental components. Evidence for strong genetic
correlations between FVIII, vWF, APCR, FIX, FXI,
homocysteine, t-PA, and thrombosis indicate that there
are sets of genes that jointly influence both disease risk
and quantitative physiological variation. The detection
of genetic effects that act jointly on both quantitative
risk factors and disease liability is critically important
for subsequent genetic analyses. When evidence of plei-
otropy is detected, the correlational structure between
the quantitative phenotypes and risk of thrombosis can
be exploited to improve the power of joint linkage anal-
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yses to detect QTLs contributing to thrombotic risk (Al-
masy et al. 1997).
Most of our observed phenotypic correlations are
consistent with known epidemiological results. For ex-
ample, there is previous evidence for a positive rela-
tionship between both vWF and FVIII levels and risk
of venous (Koster et al. 1995) and arterial thrombosis
(Folsom et al. 1997). High plasma homocysteine levels
have been associated with deep-vein thrombosis (den
Heijer et al. 1996) and with arterial thrombosis (Nygard
et al. 1997). The quantitative measure of APCR is cor-
related with risk of venous thrombosis, even when the
Factor V Leiden polymorphism is taken into account
(De Visser et al. 1999). Similarly, levels of FXII (Kohler
et al. 1998) and t-PA (Ridker et al. 1993; Carter et al.
1998) have been correlated with arterial thrombosis.
Evidence regarding the association of FVII levels with
thrombosis has been equivocal (Doggen et al. 1998;
Iacoviello et al. 1998). Very recently, results from the
LETS study have implicated high plasma levels of factor
IX (Vlieg et al. 2000) and factor XI (Meijers et al. 2000)
as risk factors for venous thrombosis.
The unique aspects of our correlational analyses lie
in the ability to disentangle genetic and environmental
sources of correlation. This technique allows us, for the
first time, to conclude that most of the phenotypic cor-
relations between thrombosis susceptibility and the
quantitative physiological measures are due to pleiotro-
pic effects of genes. There is little evidence that envi-
ronmental effects induce much of the observed phe-
notypic correlations. In the two cases where we did
observe significant environmental correlations, they
were opposite in sign to the genetic correlations. Other
investigators have reported similar results from bivar-
iate genetic analyses of a wide variety of traits (e.g.,
Comuzzie et al. 1996; Brooks 2000; Mahaney et al.
2000; Stern et al. 2000). One interpretation of the dif-
ference in sign is that the genetic and environmental
sources of variation on these traits act through different
physiological mechanisms.
In this study, we have chosen a broad definition of
thrombosis that includes both venous and arterial
forms. Our justification for this is both empirical and
theoretical. Pooling two genetically heterogeneous traits
would decrease the genetic signal-to-noise ratio of the
composite trait. However, our heritability analyses pro-
vided no evidence for such a depression in genetic signal,
indicating that there must exist substantial overlap in
the genetic determinants of venous and arterial forms
of thrombosis. Similarly, the bivariate analysis of venous
and arterial thrombosis yielded a genetic correlation not
significantly different from 1 and suggests that many of
the same genes are involved in the pathogenesis of ve-
nous and arterial events. Additionally, there is epide-
miological evidence that similar pathways are involved
in venous and arterial thrombosis, as evidenced by the
correlation between critical risk factors (such as hom-
ocysteine, vWF, and FVIII) and both venous and arterial
thrombosis. Although unique local environmental fac-
tors can separately influence thrombogenesis in veins
and arteries, the evidence suggests that much of the
underlying process is driven by a common set of genes.
Pooling of these two categories of thrombosis clearly
improved the power of the present study. However, even
if we disaggregate these components and analyze only
venous thrombosis, our results are effectively unchan-
ged (data not shown) except for predictable alterations
in observed significance values resulting from the de-
creased overall prevalence of disease.
Finally, these results provide strong support for using
genome scans to localize and evaluate the specific QTLs
involved in thrombosis susceptibility. We hope to use
the information on the genetic correlations between
thrombosis and quantitative phenotypes obtained in
this study to maximize our potential for mapping the
responsible QTLs in a genome scan currently under way.
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